Compare COHN & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COHN | CPHI |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.9M | 31.2M |
| IPO Year | 2003 | 2008 |
| Metric | COHN | CPHI |
|---|---|---|
| Price | $12.84 | $1.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.1K | ★ 10.0M |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.35% | N/A |
| EPS Growth | ★ 5537.50 | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $275,564,000.00 | $4,144,268.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.07 | ★ N/A |
| Revenue Growth | ★ 246.19 | N/A |
| 52 Week Low | $9.19 | $0.38 |
| 52 Week High | $32.60 | $19.19 |
| Indicator | COHN | CPHI |
|---|---|---|
| Relative Strength Index (RSI) | 49.39 | 50.47 |
| Support Level | $12.84 | $0.84 |
| Resistance Level | $14.50 | N/A |
| Average True Range (ATR) | 0.65 | 1.70 |
| MACD | -0.05 | 0.14 |
| Stochastic Oscillator | 36.18 | 5.62 |
Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.